Investor Relations
Recent Releases
Jan 11, 2010
MAP Pharmaceuticals Announces FDA will not Require a Second Pivotal Efficacy Study for LEVADEX(TM) NDA Submission
Jan 6, 2010
MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Dec 1, 2009
MAP Pharmaceuticals Appoints Alan Petro Vice President, Manufacturing and Technical Operations
Stock Information
| NASDAQ:MAPP
$15.03 |
- 0.20 |
| Feb 8, 2010 | 3:59 PM ET |
Quotes delayed at least 20 minutes.
Information provided by eSignal.
Information provided by eSignal.